Soluble Receptor for Advanced Glycation End Product Ameliorates Chronic Intermittent Hypoxia Induced Renal Injury, Inflammation, and Apoptosis via P38/JNK Signaling Pathways

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Wu, Xu ^a   Gu, Wenyu ^b   Lu, Huan ^a   Liu, Chengying ^c   Yu, Biyun ^d   Xu, Hui ^d   Tang, Yaodong ^d   Li, Shanqun ^a   Zhou, Jian ^a   Shao, Chuan ^d  

^a FUDAN UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SOUTHEAST UNIVERSITY   (China)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOPHAGES; BIOLOGICAL ORGANS; GLYCOSYLATION; LIGANDS; PATHOLOGY; SIGNAL TRANSDUCTION; SLEEP RESEARCH;

ADVANCED GLYCATION END PRODUCTS; CHRONIC INTERMITTENT HYPOXIAS; IMMUNOFLUORESCENCE STAINING; MITOGEN ACTIVATED PROTEIN KINASE; NEUTRALIZING ANTIBODIES; OBSTRUCTIVE SLEEP APNEA; SIGNAL TRANSDUCTION PATHWAYS; THERAPEUTIC POTENTIALS;

CELL DEATH;

ADVANCED GLYCATION END PRODUCT; CD31 ANTIGEN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; NEUTRALIZING ANTIBODY; PROTEIN BAX; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHRONIC INTERMITTENT HYPOXIA; CONTROLLED STUDY; INFLAMMATION; KIDNEY INJURY; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TUNEL ASSAY; UPREGULATION;

EID: 84988851386     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/1015390     Document Type: Article

References (61)

1. D. D. M. Nicholl, S. B. Ahmed, A. H. S. Loewen et al. , "Clinical presentation of obstructive sleep apnea in patients with chronic kidney disease," Journal of Clinical Sleep Medicine, vol. 8, no. 4, pp. 381-387, 2012
2. P. L. Kimmel, G. Miller, and W. B. Mendelson, "Sleep apnea syndrome in chronic renal disease," The American Journal of Medicine, vol. 86, pp. 308-314, 1989
3. J. J. Sim, S. A. Rasgon, D. A. Kujubu et al. , "Sleep apnea in early and advanced chronic kidney disease: Kaiser Permanente Southern California cohor," Chest, vol. 135, no. 3, pp. 710-716, 2009
4. P. J. Hanly and S. B. Ahmed, "Sleep apnea and the kidney: is sleep apnea a risk factor for chronic kidney disease" Chest, vol. 146, no. 4, pp. 1114-1122, 2014
5. J. M. Beecroft, A. Pierratos, and P. J. Hanly, "Clinical presentation of obstructive sleep apnea in patients with end-stage renal disease," Journal of Clinical SleepMedicine, vol. 5, no. 2, pp. 115-121, 2009
6. A. A. Chiang, "Obstructive sleep apnea and chronic intermittent hypoxia: a review," Chinese Journal of Physiology, vol. 49, no. 5, pp. 234-243, 2006
7. D. Stern, S. D. Yan, S. F. Yan, and A. M. Schmidt, "Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings," Advanced Drug Delivery Reviews, vol. 54, no. 12, pp. 1615-1625, 2002
8. K.-M. Wu, C.-C. Lin, C.-H. Chiu, and S.-F. Liaw, "Effect of treatment by nasal continuous positive airway pressure on serum high mobility group box-1 protein in obstructive sleep apnea," Chest, vol. 137, no. 2, pp. 303-309, 2010
9. S. Duru, I. Hikmet Firat, N. Colak, Z. Giniş, T. Delibaşi, and S. Ardiç, "Serum S100B protein: a useful marker in obstructive sleep apnea syndrome," Neurologia i Neurochirurgia Polska, vol. 46, no. 5, pp. 450-455, 2012
10. E. J. Lee, E. Y. Park, H. Mun et al. , "Soluble receptor for advanced glycation end products inhibits disease progression in autosomal dominant polycystic kidney disease by downregulating cell proliferation," The FASEB Journal, vol. 29, no. 8, pp. 3506-3514, 2015
11. V. D'Agati and A. M. Schmidt, "RAGE and the pathogenesis of chronic kidney disease," Nature Reviews Nephrology, vol. 6, no. 6, pp. 352-360, 2010
12. Y.-S. Bao, S.-P. Na, P. Zhang et al. , "Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease," Journal of Clinical Immunology, vol. 32, no. 3, pp. 587-594, 2012
13. P. Zhu, L. Xie, H.-S. Ding, Q. Gong, J. Yang, and L. Yang, "High mobility group box 1 and kidney diseases (Review)," International Journal of Molecular Medicine, vol. 31, no. 4, pp. 763-768, 2013
14. A. M. Schmidt, S. D. Yan, S. F. Yan, and D. M. Stern, "The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses," The Journal of Clinical Investigation, vol. 108, no. 7, pp. 949-955, 2001
15. A. Bruchfeld, A. R. Qureshi, B. Lindholm et al. , "Highmobility group box protein-1 correlates with renal function in chronic kidney disease (CKD),"MolecularMedicine, vol. 14, no. 3-4, pp. 109-115, 2008
16. T.-B. Zhou, "Role of high mobility group box 1 and its signaling pathways in renal diseases," Journal of Receptors and Signal Transduction, vol. 34, no. 5, pp. 348-350, 2014
17. D. Leonardis, G. Basta, F. Mallamaci et al. , "Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD)," Nutrition, Metabolism and Cardiovascular Diseases, vol. 22, no. 9, pp. 748-755, 2012
18. E. Y. Park, B. H. Kim, E. J. Lee et al. , "Targeting of receptor for advanced glycation end products suppresses cyst growth in polycystic kidney disease," The Journal of Biological Chemistry, vol. 289, no. 13, pp. 9254-9262, 2014
19. J. Li, Q. Gong, S. Zhong et al. , "Neutralization of the extracellular HMGB1 released by ischaemic damaged renal cells protects against renal ischaemia-reperfusion injury," Nephrology Dialysis Transplantation, vol. 26, no. 2, pp. 469-478, 2011
20. N. Vazzana, F. Santilli, C. Cuccurullo, and G. Dav, "Soluble forms of RAGE in internal medicine," Internal and Emergency Medicine, vol. 4, no. 5, pp. 389-401, 2009
21. M. Kalousová, M. Hodková, M. Kazderová et al. , "Soluble receptor for advanced glycation end products in patients with decreased renal function,"American Journal of Kidney Diseases, vol. 47, no. 3, pp. 406-411, 2006
22. M. F. Angelo, A. Aguirre, R. X. A. Reyes et al. , "The proinflammatory RAGE/NF-κB pathway is involved in neuronal damage and reactive gliosis in a model of sleep apnea by intermittent hypoxia," PLoS ONE, vol. 9, no. 9,Article ID e107901, 2014
23. C. Fu, L. Jiang, F. Zhu et al. , "Chronic intermittent hypoxia leads to insulin resistance and impaired glucose tolerance through dysregulation of adipokines in non-obese rats," Sleep and Breathing, vol. 19, no. 4, pp. 1467-1473, 2015
24. D. G. S. Farmer, M.-A. Ewart, K. M. Mair, and S. Kennedy, "Soluble receptor for advanced glycation end products (sRAGE) attenuates haemodynamic changes to chronic hypoxia in the mouse," Pulmonary Pharmacology and Therapeutics, vol. 29, no. 1, pp. 7-14, 2014
25. C. F. Islam, R. T. Mathie, M. D. Dinneen, E. A. Kiely, A. M. Peters, and P. A. Grace, "Ischaemia-reperfusion injury in the rat kidney: the effect of preconditioning," British Journal ofUrology, vol. 79, no. 6, pp. 842-847, 1997
26. A. Nakao, J. S. Neto, S. Kanno et al. , "Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both," American Journal of Transplantation, vol. 5, no. 2, pp. 282-291, 2005
27. E. Z. Bagci, Y. Vodovotz, T. R. Billiar, G. B. Ermentrout, and I. Bahar, "Bistability in apoptosis: roles of Bax, Bcl-2, and mitochondrial permeability transition pores," Biophysical Journal, vol. 90, no. 5, pp. 1546-1559, 2006
28. A. Bierhaus, P. M. Humpert, M. Morcos et al. , "Understanding RAGE, the receptor for advanced glycation end products," Journal ofMolecularMedicine, vol. 83, no. 11, pp. 876-886, 2005
29. P. Pichiule, J. C. Chavez, A. M. Schmidt, and S. J. Vannucci, "Hypoxia-inducible factor-1 mediates neuronal expression of the receptor for advanced glycation end products following hypoxia/ischemia," The Journal of Biological Chemistry, vol. 282, no. 50, pp. 36330-36340, 2007
30. G. Basta, G. Lazzerini, M. Massaro et al. , "Advanced glycation end products activate endothelium through signaltransduction receptor RAGE: a mechanism for amplification of inflammatory responses," Circulation, vol. 105, no. 7, pp. 816-822, 2002
31. G. Faraco, S. Fossati, M. E. Bianchi et al. , "High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo," Journal of Neurochemistry, vol. 103, no. 2, pp. 590-603, 2007
32. G.-Y. Gwak,T. G. Moon, D. H. Lee, and B. C. Yoo, "Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway," World Journal of Gastroenterology, vol. 18, no. 7, pp. 679-684, 2012
33. J.-B. Kim, S. C. Joon, Y.-M. Yu et al. , "HMGB1, a novel cytokinelike mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain," The Journal of Neuroscience, vol. 26, no. 24, pp. 6413-6421, 2006
34. Y. Oyama, T. Hashiguchi, N. Taniguchi et al. , "High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy," Laboratory Investigation, vol. 90, no. 6, pp. 853-866, 2010
35. U. Andersson, H. Wang, K. Palmblad et al. , "High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes," The Journal of Experimental Medicine, vol. 192, no. 4, pp. 565-570, 2000
36. A. Lau, S. Wang, W. Liu, A. Haig, Z.-X. Zhang, and A. M. Jevnikar, "Glycyrrhizic acid ameliorates HMGB1-mediated cell death and inflammation after renal ischemia reperfusion injury,"American Journal ofNephrology, vol. 40,no. 1, pp. 84-95, 2014
37. J. Y. Jhun, S. H. Lee, H. Y. Kimet al. , "HMGB1/RAGEinduces IL-17 expression to exaggerate inflammation in peripheral blood cells of hepatitis B patients," Journal of TranslationalMedicine, 2015
38. E. M. Akirav, P. Preston-Hurlburt, J. Garyu et al. , "RAGE expression in human T cells: a link between environmental factors and adaptive immune responses," PLoS ONE, vol. 7, no. 4, Article ID e34698, 2012
39. C.-C. Lee, Y.-T. Lai, H.-T. Chang et al. , "Inhibition of highmobility group box 1 in lung reduced airway inflammation and remodeling in a mouse model of chronic asthma," Biochemical Pharmacology, vol. 86, no. 7, pp. 940-949, 2013
40. A. Villarreal, R. X. Aviles Reyes, M. F. Angelo, A. G. Reinesf, and A. J. Ramos, "S100B alters neuronal survival and dendrite extension via RAGE-mediated NF-κB signaling," Journal of Neurochemistry, vol. 117, no. 2, pp. 321-332, 2011
41. Z. Shi, A. Lian, and F. Zhang, "Nuclear factor-κB activation inhibitor attenuates ischemia reperfusion injury and inhibits Hmgb1 expression," Inflammation Research, vol. 63, no. 11, pp. 919-925, 2014
42. T. M. Wendt, N. Tanji, J. Guo et al. , "RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy," American Journal of Pathology, vol. 162, no. 4, pp. 1123-1137, 2003
43. A. Simm, G. Münch, F. Seif et al. , "Advanced glycation endproducts stimulate theMAP-kinase pathway in tubulus cell line LLC-PK1," FEBS Letters, vol. 410, no. 2-3, pp. 481-484, 1997
44. L. Adhikary, F. Chow, D. J. Nikolic-Paterson et al. , "Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy," Diabetologia, vol. 47, no. 7, pp. 1210-1222, 2004
45. C.-H. Wu, C.-M. Huang, C.-H. Lin, Y.-S. Ho, C.-M. Chen, and H.-M. Lee, "Advanced glycosylation end products induce NF-κB dependent iNOS expression in RAW264. 7 cells," Molecular and Cellular Endocrinology, vol. 194, no. 1-2, pp. 9-17, 2002
46. H. M. Lander, J. M. Tauras, J. S. Ogiste, O. Hori, R. A. Moss, and A. M. Schmidt, "Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogenactivated protein kinase pathway regulated by oxidant stress," The Journal of Biological Chemistry, vol. 272, no. 28, pp. 17810-17814, 1997
47. A. Taguchi, D. C. Blood, G. del Toro et al. , "Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases," Nature, vol. 405, no. 6784, pp. 354-360, 2000
48. E. Y. Park, M. J. Seo, and J. H. Park, "Effects of specific genes activating RAGE on polycystic kidney disease," American Journal of Nephrology, vol. 32, no. 2, pp. 169-178, 2010
49. R. G. Iannitti, A. Casagrande, A. De Luca et al. , "Hypoxia promotes danger-mediated inflammation via receptor for advanced glycation end products in cystic fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 11, pp. 1338-1350, 2013
50. M. A. H. Bowman and A. M. Schmidt, "The next generation of RAGE modulators: implications for soluble RAGE therapies in vascular inflammation," Journal of Molecular Medicine, vol. 91, no. 12, pp. 1329-1331, 2013
51. C. Guo, X. Zeng, J. Song et al. , "A soluble receptor for advanced glycation end-products inhibits hypoxia/reoxygenationinduced apoptosis in rat cardiomyocytes via the mitochondrial pathway," International Journal of Molecular Sciences, vol. 13, no. 9, pp. 11923-11940, 2012
52. A. Raucci, S. Cugusi, A. Antonelli et al. , "A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)," The FASEB Journal, vol. 22, no. 10, pp. 3716-3727, 2008
53. G. Gong, L. Xiang, L. Yuan et al. , "Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on focal cerebral ischemia/reperfusion-induced inflammation, oxidative stress, and apoptosis in rats," PLoSONE, vol. 9, no. 3,Article IDe89450, 2014
54. D. Geroldi, C. Falcone, E. Emanuele et al. , "Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension," Journal of Hypertension, vol. 23, no. 9, pp. 1725-1729, 2005
55. K.-H. Chiang, P.-H. Huang, S.-S. Huang, T.-C. Wu, J.-W. Chen, and S.-J. Lin, "Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients," Coronary Artery Disease, vol. 20, no. 4, pp. 267-273, 2009
56. M. Kalousová, M. Jáchymová, M. Oto et al. , "Receptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patients," Nephrology Dialysis Transplantation, vol. 22, no. 7, pp. 2020-2026, 2007
57. B. Liliensiek, M. A. Weigand, A. Bierhaus et al. , "Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response," The Journal of Clinical Investigation, vol. 113, no. 11, pp. 1641-1650, 2004
58. C. Renard, O. Chappey, M.-P. Wautier et al. , "Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats," Molecular Pharmacology, vol. 52, no. 1, pp. 54-62, 1997
59. G. Daffu, C. H. del Pozo, K. M. O'Shea, R. Ananthakrishnan, R. Ramasamy, and A. M. Schmidt, "Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond," International Journal ofMolecular Sciences, vol. 14, no. 10, pp. 19891-19910, 2013
60. W. Jiang, C. W. Bell, and D. S. Pisetsky, "The relationship between apoptosis and high-mobility group protein 1 release from murine macrophages stimulated with lipopolysaccharide or polyinosinic-polycytidylic acid,"The Journal of Immunology, vol. 178, no. 10, pp. 6495-6503, 2007
61. M. J. Robinson, P. Tessier, R. Poulsom, and N. Hogg, "The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells," The Journal of Biological Chemistry, vol. 277, no. 5, pp. 3658-3665, 2002.